As per the deal, both companies also intend to collaborate on research to explore next-generation cMet antibodies.
Under the collaboration and license agreement, Abbott will lead the development and commercialization of monoclonal antibodies targeting the cMet receptor. Pierre Fabre will receive an initial $25m upfront payment and research funding to support further discovery efforts for two years. Additional terms of the agreement, including milestones and royalty payments, remain confidential.
H224G11 works by specifically binding to cMet protein and interrupting the signaling pathway, which leads to cancer cell death and prevention of tumor growth. The antibody also inhibits cancer cell migration and angiogenesis.
John Leonard, senior vice president of global research and development at Abbott, said: "cMet is a compelling cancer target and the early research on this compound looks promising. We look forward to adding to our strong oncology pipeline, which includes exploration of multiple mechanisms to treat cancer."
Jean-Pierre Garnier, chief executive officer of Pierre Fabre, said: "Using the strengths of its dedicated research team in biotechnology, Pierre Fabre SA has been able to develop potent and protein specific inhibitors of the cMet receptor. We are delighted to partner this important asset with Abbott scientists."